Despite some initial promising early phase results, the development of HDAC inhibitors in lung cancer has been discontinued because of the lack of single‐agent efficacy and the lack of a biomarker that would facilitate patient selection.7, 8. The gene discussed is HDAC9; the disease is lung carcinoma.